BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8267650)

  • 1. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
    Ritke MK; Yalowich JC
    Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Bergoltz VV; Allan WP; Yalowich JC
    Biochem Pharmacol; 1994 Aug; 48(3):525-33. PubMed ID: 8068039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
    Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
    Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
    Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
    Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC
    Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
    Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
    J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
    Matsumoto Y; Kunishio K; Nagao S
    J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
    Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
    Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
    Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y; Takano H; Fojo T
    Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.